Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Chapman, P.; Hauschild, A.; Robert, C.; Haanen, J.; Ascierto, P.; Larkin, J.; Dummer, R.; Garbe, C.; Testori, A.; Maio, M.; Hogg, D.; Lorigan, P.; Lebbé, C.; Jouary, T.; Schadendorf, D.; Ribas, A.; O'Day, S.; Sosman, J.; Kirkwood, J.; Eggermont, A.; Dréno, B.; Nolop, K.; Li, Jiang; Nelson, B.; Hou, J.; J Lee, Richard; Flaherty, K.; McArthur, G.

doi:10.1056/NEJMoa1103782

Public

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

Shared by NobleBlocks on Jun 5, 2011 • 12:00 AM UTC

Authors:

P. Chapman

A. Hauschild

C. Robert

Abstract

Background Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation. Methods We conducted a phase 3 randomized clinical trial comparing vemurafenib with dacarbazine in...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!